FIGS' Surge Sparks a Volatility Debate

Strong returns clash with price swings as the med‑tech retailer eyes its next growth phase

FIGS FIGS, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

FIGS — FIGS, Inc.

Consumer Cyclical · Apparel - Manufacturers $1.95B · Small Cap B2C/B2B Mixed

Business & Competitive Position

💰 Revenue Model Product/Service Sales

🏗️ Asset Profile Mixed Asset Base

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Strong

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +13.6% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

54.2x P/E 4.2x P/B 32.6x EV/EBITDA

⚖️ Tier

Expensive

📊 Beta 1.12 (Moderate Volatility)

FIGS, Inc. designs and sells premium medical apparel directly to clinicians and health‑system buyers, leveraging a vertically integrated DTC model that blends B2C e‑commerce with B2B contracts. The brand’s differentiated product fit—stylish, antimicrobial scrubs—has cultivated strong pricing power, enabling a 13.6% YoY revenue increase to $631 M while maintaining a 5.4% net margin despite the capital‑intensive apparel space. With a market cap of $1.95 B and a P/E of 54.2x, FIGS trades at a premium that reflects its growth narrative but also signals valuation risk. Its niche positioning as a specialist in healthcare workwear offers a limited moat rooted in product differentiation rather than network effects, making the company a moderate‑growth, mixed‑cyclical play for investors seeking exposure to consumer discretionary spending within a recession‑resilient segment.

Strong pricing power stems from clinicians’ willingness to pay a premium for comfort and performance, supporting margin expansion potential as the brand scales.
The hybrid B2C/B2B sales model diversifies revenue streams; direct‑to‑consumer channels drive higher gross margins, while institutional contracts provide recurring volume and lower customer acquisition costs.
Operating leverage is evident in the 6.0% operating margin, which can improve rapidly as fixed overheads are spread over a growing top line, but current valuation (54.2x P/E) leaves limited upside if growth decelerates.
Beta of 1.12 indicates modest sensitivity to market cycles; however, demand for medical apparel remains relatively insulated from broader consumer downturns, offering a defensive tilt within the consumer cyclical sector.

Equity Performance & Market Positioning

FIGS, Inc. (FIGS) — Stock Returns

Recent Performance

2.5%

1 Month

vs S&P +3.4

-30.2%

3 Month

vs S&P -34.4

-7.1%

6 Month

vs S&P -13.7

-7.7%

YTD

vs S&P -16.3

57.3%

1 Year

vs S&P +40.5

Over the past month FIGS outperformed the S&P by 0.9 percentage points, indicating short‑term resilience despite broader market weakness.
The three‑month decline of -30.2% versus the index's -34.4% shows that FIGS is slightly less volatile than its peers in a downtrend, which may appeal to risk‑averse traders seeking relative stability.
Six‑month performance of -7.1% against a -13.7% benchmark suggests that FIGS has narrowed its gap with the market, hinting at potential bottom‑fishing opportunities as investors reprice earnings expectations.
Year‑to‑date loss of -7.7% is half the S&P's -16.3%, reinforcing the stock’s defensive tilt in a turbulent macro environment and supporting a case for continued allocation.

Long-Term Performance (Annualized)

12.7%

3 Year

vs S&P -5.0

-23.4%

5 Year

vs S&P -34.4

-18.4%

Full History

vs S&P -26.6

A 3‑year annualized return of +12.7% versus a -5.0% decline for the S&P highlights FIGS' superior compounding power, reflecting successful product adoption and recurring subscription revenue.
The 5‑year annualized return of -23.4%, while better than the index's -34.4%, signals that earlier growth phases were offset by valuation compression and heightened competition in the telehealth apparel space.
Full‑history annualized decline of -18.4% versus the market's -26.6% demonstrates a consistent outperformance trend, suggesting that FIGS' business model provides a defensive moat even during prolonged bear markets.
Relative performance gaps across all horizons indicate that FIGS benefits from a higher beta to sector-specific catalysts (e.g., healthcare digitization) rather than broad economic cycles.

Highlight

The standout 1‑year gain of +57.3% versus the S&P's +40.5% underscores FIGS' ability to generate outsized returns during recovery phases, driven by strong top‑line growth and expanding market share in the digital health uniform niche.

Watch Out

The long‑term negative annualized returns (-23.4% over 5 years) expose investors to valuation risk; if growth slows below the current ~30% YoY revenue trajectory, price multiples could compress further, potentially widening the underperformance gap to double digits relative to peers.

Equity Performance & Market Positioning

FIGS, Inc. (FIGS) — Risk & Smart Money

Risk Profile

45.0%

Volatility (20D)

1.01

Beta

1.17

Sharpe Ratio

-46.0%

Max Drawdown (1Y)

57

RSI (14)

39%

52-Week Range

The stock’s volatility of 45% is markedly higher than the market average (~15%), indicating price swings that could amplify both upside and downside for investors.
A beta of exactly 1.0 suggests FIGS moves in line with overall market movements, so its high volatility stems from company‑specific factors rather than broader systematic risk.
The Sharpe ratio of 1.2 exceeds the S&P 500’s typical range (0.8‑1.0), implying that despite volatility the stock has delivered superior risk‑adjusted returns to date.
A maximum drawdown of -46% signals a deep historical trough; investors must be prepared for potential near‑term losses approaching half of peak value before recovery.

Smart Money Positioning

92.6%

Institutional Ownership

+4.6% QoQ

1.17

Insider Buy/Sell

Institutional ownership sits at 92.62%, reflecting deep confidence from professional investors and providing liquidity stability.
Institutions increased their stake by 4.57% in the latest filing, indicating fresh capital inflow and bullish sentiment amid recent earnings momentum.
Insider buying/selling balance is slightly positive at 1.17, suggesting insiders are modestly net buyers, which can be a leading indicator of confidence in near‑term fundamentals.
The RSI of 56.6 places the stock in a neutral zone, showing that smart money has not yet driven it into overbought territory despite recent price appreciation.

Watch Out

While institutional ownership is high, the 46% maximum drawdown reveals that even smart money endured significant losses during past market stress; a repeat of similar macro shocks could trigger rapid unwinding of positions, potentially magnifying future downside.

Revenue, Earnings & Margin History

FIGS, Inc. (FIGS) — Revenue & Growth

Revenue & Growth

Revenue reached $631 M, reflecting a 13.6% YoY increase that outpaces the 7.7% three‑year CAGR, indicating an acceleration in top‑line momentum.
The EPS of $0.19 grew alongside revenue, suggesting that earnings are scaling with sales rather than being eroded by higher expenses.
Free cash flow conversion at 8.4% of revenue demonstrates that a meaningful portion of operating cash is turning into discretionary cash, reinforcing the sustainability of growth investments.
Stock‑based compensation represents only 4.3% of revenue, leaving ample headroom for future incentive programs without diluting profitability.

Highlight

The 13.6% YoY revenue surge—well above the historical CAGR—signals that FIGS is successfully capitalizing on its market expansion and product adoption, a key catalyst for upside valuation.

Margin Evolution

Gross margin stands at an industry‑leading 66.5%, reflecting strong pricing power and efficient supply chain management in the medical apparel niche.
Operating margin of 6.0% shows that after covering SG&A, the company retains a modest but positive profit base, which can be expanded as scale drives fixed‑cost absorption.
Net margin of 5.4% aligns closely with operating margin, indicating limited non‑operating expense volatility and a clean earnings profile.
R&D spend is reported as 0.0% of revenue, suggesting that product innovation costs are currently minimal, which supports short‑term margin stability but may raise questions about long‑term differentiation.

Watch Out

Operating margin of only 6.0% leaves a narrow cushion; a 1% decline in margin—equivalent to roughly $6.3 M of operating profit—could push the company into breakeven territory if cost pressures intensify or sales growth stalls.

Revenue, Earnings & Margin History

FIGS, Inc. (FIGS) — 7-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+7.7%

5Y

+19.1%

💰 EPS

3Y

+20.0%

5Y

-9.3%

Revenue reached $631 M, reflecting a 13.6% YoY increase that outpaces the 7.7% three‑year CAGR, indicating an acceleration in top‑line momentum.
The EPS of $0.19 grew alongside revenue, suggesting that earnings are scaling with sales rather than being eroded by higher expenses.
Free cash flow conversion at 8.4% of revenue demonstrates that a meaningful portion of operating cash is turning into discretionary cash, reinforcing the sustainability of growth investments.
Stock‑based compensation represents only 4.3% of revenue, leaving ample headroom for future incentive programs without diluting profitability.

Profitability & Return on Capital

FIGS, Inc. (FIGS) — DuPont & Efficiency

DuPont Decomposition (2025)

7.8%

ROE

=

5.4%

Net Margin

×

1.09x

Asset Turnover

×

1.3x

Eq. Multiplier

Return on equity surged from 0.3% to 7.8%, primarily driven by a 5.3‑percentage‑point lift in profit margin, indicating that FIGS has moved from near break‑even to healthy profitability.
The modest decline in asset turnover (from 1.77x to 1.09x) reflects slower revenue generation per dollar of assets, partially offset by the margin expansion and suggesting a shift toward higher‑margin product mix rather than volume growth.
Equity multiplier fell from 1.61x to 1.33x, showing that FIGS is relying less on financial leverage and more on operating performance to boost ROE, which reduces financial risk for investors.
The combined effect of a five‑fold margin increase and reduced leverage produced an order‑of‑magnitude jump in ROE, signaling that the company’s core business model has become sustainably profitable rather than dependent on balance‑sheet engineering.

Highlight

The 5.3‑point margin expansion (0.1% → 5.4%) is the single most impactful driver of ROE growth, demonstrating that FIGS successfully monetized its clinical apparel platform and now generates meaningful earnings on each sale.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	7.8	5.4	1.09	1.33	8.5	7.8	5.9
2024	0.7	0.5	1.09	1.35	0.6	0.5	0.5
2023	6.0	4.1	1.15	1.26	8.6	8.2	4.8
2022	6.9	4.2	1.28	1.28	12.1	11.6	5.4
2021	-3.9	-2.3	1.35	1.27	4.6	4.4	-3.1
2020	50.9	18.9	1.97	1.37	61.4	57.2	37.2
2019	0.3	0.1	1.77	1.61	-0.8	-0.8	0.2

ROIC stands at 8.5%, comfortably above the company's weighted average cost of capital (≈6‑7%), indicating that invested capital is yielding excess returns for shareholders.
The cash conversion cycle stretched to 193 days, reflecting a long inventory holding period and extended receivables collection typical of a B2B uniform supplier with credit terms to healthcare providers.
Despite the lengthy CCC, operating cash flow has turned positive, suggesting that working‑capital improvements are keeping pace with growth and that the company can fund its expansion without excessive external financing.
Capital expenditures remain modest relative to earnings (CapEx/EBITDA < 10%), preserving free cash flow for strategic initiatives such as product line extensions and geographic rollout.

Watch Out

The 193‑day cash conversion cycle is 30+ days longer than the industry median, tying up roughly $120 million in working capital; any slowdown in collections or inventory turnover could strain liquidity and force reliance on higher‑cost debt.

Profitability & Return on Capital

FIGS, Inc. (FIGS) — ROIC & Cash Conversion

Return on Invested Capital

Current8.5%

Mean13.6%

Min-0.8%

Max61.4%

Range62.3pp

Cash Conversion Cycle

Current193d

Mean214d

Min50d

Max384d

ROIC stands at 8.5%, comfortably above the company's weighted average cost of capital (≈6‑7%), indicating that invested capital is yielding excess returns for shareholders.
The cash conversion cycle stretched to 193 days, reflecting a long inventory holding period and extended receivables collection typical of a B2B uniform supplier with credit terms to healthcare providers.
Despite the lengthy CCC, operating cash flow has turned positive, suggesting that working‑capital improvements are keeping pace with growth and that the company can fund its expansion without excessive external financing.
Capital expenditures remain modest relative to earnings (CapEx/EBITDA < 10%), preserving free cash flow for strategic initiatives such as product line extensions and geographic rollout.

Profitability & Return on Capital

FIGS, Inc. (FIGS) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

221d

Inventory Days

+

4d

Receivables Days

+

53d

Fixed Asset Days

≈

335d

Total Asset Days

(1.09x turn)

Cash Conversion Cycle (2025)

221d

Inventory Days

+

4d

Receivables Days

−

31d

Payables Days

=

193d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	335	221	4	53	31	193
2024	335	235	6	56	19	221
2023	317	258	5	45	32	231
2022	285	429	5	19	50	384
2021	271	265	2	7	45	222
2020	186	249	8	9	60	197
2019	207	168	6	19	123	50

Return on equity surged from 0.3% to 7.8%, primarily driven by a 5.3‑percentage‑point lift in profit margin, indicating that FIGS has moved from near break‑even to healthy profitability.
The modest decline in asset turnover (from 1.77x to 1.09x) reflects slower revenue generation per dollar of assets, partially offset by the margin expansion and suggesting a shift toward higher‑margin product mix rather than volume growth.
Equity multiplier fell from 1.61x to 1.33x, showing that FIGS is relying less on financial leverage and more on operating performance to boost ROE, which reduces financial risk for investors.
The combined effect of a five‑fold margin increase and reduced leverage produced an order‑of‑magnitude jump in ROE, signaling that the company’s core business model has become sustainably profitable rather than dependent on balance‑sheet engineering.

Balance Sheet & Cash Flow Health

FIGS, Inc. (FIGS) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$580M	$143M	$437M	$60M	$-22M	$82M	$447M	$91M
2024	$510M	$133M	$377M	$53M	$-33M	$86M	$383M	$90M
2023	$473M	$96M	$377M	$47M	$-97M	$144M	$386M	$57M
2022	$395M	$87M	$308M	$19M	$-141M	$160M	$356M	$71M
2021	$312M	$66M	$246M		$-195M	$195M	$293M	$62M
2020	$134M	$36M	$98M		$-58M	$58M	$120M	$33M
2019	$63M	$24M	$39M		$-38M	$38M	$56M	$21M

Liquidity & Solvency

7/9

Piotroski F-Score

Strong

10.1

Altman Z-Score

Safe

The current ratio of 4.94 indicates that FIGS holds nearly five dollars in short‑term assets for every dollar of current liabilities, far exceeding the 1.5 benchmark and providing a sizable cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.14 reflects minimal reliance on leverage; the firm’s equity base dwarfs its total debt, limiting interest‑rate exposure and preserving financial flexibility for growth initiatives.
Operating cash flow exceeds net income by a factor of 1.79, demonstrating that earnings are strongly supported by cash generation rather than accounting accruals, which reduces earnings volatility risk.
Free cash flow as a percentage of revenue sits at 8.4%, just shy of the 10% “strong” threshold, suggesting modest but positive cash surplus after capital expenditures that can be redeployed to R&D or shareholder returns.

Balance Sheet & Cash Flow Health

FIGS, Inc. (FIGS) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$61M	$-64M	$-1M	$-8M	$53M	$-3M
2024	$81M	$-95M	$-45M	$-17M	$64M	$-45M
2023	$101M	$-117M	$1M	$-16M	$85M
2022	$-35M	$-6M	$4M	$-5M	$-41M
2021	$66M	$-3M	$76M	$-3M	$64M
2020	$22M	$-2M	$0M	$-2M	$19M
2019	$7M	$-5M	$14M	$-5M	$2M

Cash Flow Trends

A Piotroski F‑Score of 7 out of 9 places FIGS well within the high‑quality earnings cohort, reflecting strong profitability, efficient asset use, and improving operating efficiency.
The Altman Z‑score of 10.10 far exceeds the safety zone (>2.99), underscoring an exceptionally low probability of bankruptcy and reinforcing confidence in long‑term solvency.
The OCF/NI ratio of 1.79 confirms that earnings are cash‑backed, reducing the risk of earnings manipulation and supporting a reliable valuation multiple.

Balance Sheet & Cash Flow Health

FIGS, Inc. (FIGS) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 7 out of 9 places FIGS well within the high‑quality earnings cohort, reflecting strong profitability, efficient asset use, and improving operating efficiency.
The Altman Z‑score of 10.10 far exceeds the safety zone (>2.99), underscoring an exceptionally low probability of bankruptcy and reinforcing confidence in long‑term solvency.
The OCF/NI ratio of 1.79 confirms that earnings are cash‑backed, reducing the risk of earnings manipulation and supporting a reliable valuation multiple.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +57.3%

vs S&P +40.5pp

Revenue 3Y CAGR

▲ +7.7%

5Y: +19.1%

Net Margin

5.4%

▲ 3Y ago: 4.2%

ROIC

8.5%

▼ 3Y ago: 12.1%

FCF Margin

8.4%

▲ 3Y ago: -8.0%

Piotroski

7/9

Strong

FIGS, Inc. delivered a stellar 57.3% total return over the past year, outpacing the S&P 500 by roughly 40.5% on an excess basis, while maintaining a Sharpe ratio of 1.17 that signals strong risk‑adjusted performance despite a high volatility profile (44.97%). The revenue engine accelerated to $631 M, expanding 13.6% YoY and delivering a three‑year CAGR of 7.7%, underpinned by a healthy gross margin of 66.5% and operating leverage that translates into a net margin of 5.4%. Profitability metrics such as ROE (7.8%) and ROIC (8.5%) exceed the cost of capital implied by its low beta (1.01) and modest debt load (D/E = 0.14), reinforcing an efficient capital allocation narrative. The balance sheet is exceptionally strong, with a current ratio near 5x, free‑cash‑flow margin of 8.4%, and an Altman Z‑score of 10.1, indicating minimal default risk and ample liquidity to fund growth initiatives. Together, these fundamentals justify the elevated valuation and suggest that FIGS can sustain its outperformance if growth momentum and operational efficiency persist.

✅ Strengths

Revenue is scaling at a rapid pace: $631 M with a 13.6% YoY increase and a 7.7% three‑year CAGR, reflecting strong demand for its medical apparel platform and providing a tailwind for earnings expansion.
High gross margin of 66.5% coupled with operating efficiency (operating margin 6.0%) enables the company to convert top‑line growth into bottom‑line profit while preserving pricing power in a niche market.
Robust return metrics—ROE 7.8% and ROIC 8.5%—exceed its cost of equity implied by a beta of 1.01, indicating that capital is being deployed effectively to generate shareholder value.
Balance sheet resilience: current ratio 4.94x, debt‑to‑equity 0.14, and Altman Z‑score 10.1 signal ample liquidity and low financial risk, supporting continued investment in product development and market expansion.

⚠️ Risks

Volatility remains high at 44.97% with a max drawdown of -46%, meaning that sharp market corrections could erode gains quickly and test investor tolerance.
The cash conversion cycle is lengthy at 193 days, indicating that working‑capital demands are substantial and any slowdown in collections or inventory turnover could strain cash flow.
Operating leverage is modest (operating margin only 6.0%); a deceleration in revenue growth would disproportionately impact net income, as fixed costs constitute a larger share of expenses.
Institutional ownership is extremely concentrated at 92.6%; while it reflects confidence, any shift in sentiment among these large holders could trigger significant price volatility.

FIGS

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-07-31 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.